Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Capital Expenditures: 2018-2025

Historic Capital Expenditures for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to $674,000.

  • Bicycle Therapeutics' Capital Expenditures rose 54.94% to $674,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 133.55%. This contributed to the annual value of $1.2 million for FY2024, which is 57.84% down from last year.
  • Latest data reveals that Bicycle Therapeutics reported Capital Expenditures of $674,000 as of Q3 2025, which was up 35.34% from $498,000 recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Capital Expenditures registered a high of $9.8 million during Q2 2022, and its lowest value of $12,000 during Q1 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $435,000 (2024), whereas its average is $540,000.
  • Its Capital Expenditures has fluctuated over the past 5 years, first spiked by 5,630.41% in 2022, then slumped by 99.43% in 2024.
  • Over the past 5 years, Bicycle Therapeutics' Capital Expenditures (Quarterly) stood at $1.1 million in 2021, then skyrocketed by 35.71% to $1.4 million in 2022, then crashed by 96.48% to $51,000 in 2023, then skyrocketed by 621.57% to $368,000 in 2024, then spiked by 54.94% to $674,000 in 2025.
  • Its last three reported values are $674,000 in Q3 2025, $498,000 for Q2 2025, and $604,000 during Q1 2025.